New Recruiting Trial: A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients

WHY IT MATTERS

This trial offers elderly patients with relapsed or refractory MDS/AML a potentially less toxic conditioning regimen before stem cell transplant — cladribine-bridged LABU may improve tolerability compared to standard high-dose approaches in this vulnerable population.

Researchers are testing a new treatment approach for elderly patients with a type of blood cancer (MDS or AML) that has come back or stopped responding to previous treatments. The study uses a combination of chemotherapy drugs followed by a stem cell transplant from a donor to try to help patients recover. This trial is now actively looking for patients to participate.

NCT ID: NCT07500753 Title: A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients Status: RECRUITING Phase: NA Sponsor: The First Affiliated Hospital of Soochow University Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07500753 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you or a loved one has relapsed/refractory MDS or AML and are elderly, ask your hematologist or oncologist about eligibility for this trial (NCT07500753) at The First Affiliated Hospital of Soochow University, which begins recruiting April 2026.